Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D.
Garcia A, et al.
Neurol Neuroimmunol Neuroinflamm. 2023 Feb 21;10(3):e200091. doi: 10.1212/NXI.0000000000200091. Print 2023 May.
Neurol Neuroimmunol Neuroinflamm. 2023.
PMID: 36810163
Free PMC article.